Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yue Xiang
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
University of California, San Francisco
ORCID:
0009-0005-3012-7613
Observed ORCID:
0009-0005-3012-7613
OpenAlex ID:
A5079044268
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
2023
·
Timil H. Patel
, Jamie R. Brewer
, et al.
·
Clinical Cancer Research
·
81
PDF
An Explanation of Why Dose-Corrected Area Under the Curve for Alternate Administration Routes Can Be Greater than for Intravenous Dosing
2024
·
Hirokazu Wakuda
, Yue Xiang
, et al.
·
The AAPS Journal
·
16
PDF
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer
2026
·
Yufan Liu
, Jeannette Nashed
, et al.
·
Clinical Cancer Research
·
14
PDF
Application of Kirchhoff’s Laws to pharmacologic and pharmacokinetic analyses
2025
·
Leslie Z. Benet
, Jasleen K. Sodhi
, et al.
·
Pharmacological Reviews
·
7
PDF
Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers
2021
·
Yue Xiang
, Hideaki Okochi
, et al.
·
Clinical Pharmacology & Therapeutics
·
7
Show more works
View as search
Works count:
5
Citation count:
125
H-index:
5
I10-index:
3
Year
Topic
Type